Novel product for the alleviation of symptom 'flare-up' in chronic intestinal disease

We have identified a strain of Streptococcus thermophilus (NCIMB 41856) which is anti-inflammatory, acting on both human intestinal leukocytes and human intestinal epithelial cell lines (Caco-2 and T84). It reduces epithelial cell death as well as NF-κB signalling and IL-8 production triggered by pathogens. It abrogates binding of pathogens to epithelial cells and crosses the epithelial cell barrier with E. coli where it downregulates Th1 and Th17 responses in intestinal leukocytes. Its mode of action is local to the treated area, avoiding the immunosuppression seen with systemic medication.

For more information click here (PDF, 709kB) or contact